Preusch, M., Ieronimakis, N., Wijelath, E. S., Cabbage, S., Ricks, J., Bea, F., . . . Rosenfeld, M. E. (2015). Dabigatran etexilate retards the initiation and progression of atherosclerotic lesions and inhibits the expression of oncostatin M in apolipoprotein E-deficient mice. Drug design, development and therapy, 9, . https://doi.org/10.2147/DDDT.S86969
Chicago-Zitierstil (17. Ausg.)Preusch, Michael, Nicholas Ieronimakis, Errol S. Wijelath, Sara Cabbage, Jerry Ricks, Florian Bea, Morayma Reyes, Joanne van Ryn, und Michael E. Rosenfeld. "Dabigatran Etexilate Retards the Initiation and Progression of Atherosclerotic Lesions and Inhibits the Expression of Oncostatin M in Apolipoprotein E-deficient Mice." Drug Design, Development and Therapy 9 (2015). https://doi.org/10.2147/DDDT.S86969.
MLA-Zitierstil (9. Ausg.)Preusch, Michael, et al. "Dabigatran Etexilate Retards the Initiation and Progression of Atherosclerotic Lesions and Inhibits the Expression of Oncostatin M in Apolipoprotein E-deficient Mice." Drug Design, Development and Therapy, vol. 9, 2015, https://doi.org/10.2147/DDDT.S86969.